Biagio Ricciuti, Thoracic Medical Oncologist at Dana-Farber Cancer Institute, shared on LinkedIn:
“Great presentations at the Harvard Lung Cancer Symposium from our terrific research group, showcasing their efforts to identify biomarkers of response and resistance to PD-(L)1 blockade in both metastatic and early-stage lung cancer!
Very proud of the work our fellows Edoardo Garbo, Cassio Murilo Hidalgo Filho, Leonardo Brunetti are doing to advance our understanding of lung cancer immunotherapy.
I feel incredibly fortunate to work alongside such a talented, dedicated, and compassionate team!”

You can also read: